Rosa Bernardi

List of Publications by Year
in descending order

#	Article	IF	Citations
1	PML restrains p53 activity and cellular senescence in clear cell renal cell carcinoma. EMBO Molecular Medicine, 2024, 16, 1324-1351.	6.8	0
2	PML is a constitutive component of chromatin domains enriched in repetitive elements and duplicated gene clusters in cancer cells. Heliyon, 2024, 10, e36499.	3.2	0
3	PML modulates epigenetic composition of chromatin to regulate expression of pro-metastatic genes in triple-negative breast cancer. Nucleic Acids Research, 2023, 51, 11024-11039.	13.9	4
4	Renal dysfunction and podocyturia in pre-eclampsia may be explained by increased urinary VEGF. Nephrology Dialysis Transplantation, 2022, 37, 1109-1117.	0.8	7
5	PML isoforms: a molecular basis for PML pleiotropic functions. Trends in Biochemical Sciences, 2022, 47, 609-619.	7.4	12
6	The role of 18F-FAZA PET/CT in detecting lymph node metastases in renal cell carcinoma patients: a prospective pilot trial. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 554-560.	6.6	11
7	The EHA Research Roadmap: Normal Hematopoiesis. HemaSphere, 2021, 5, e669.	2.4	1
8	HIF-1Î± is over-expressed in leukemic cells from <i>TP53</i>-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia. Haematologica, 2020, 105, 1042-1054.	3.4	42
9	A2A-D2 Heteromers on Striatal Astrocytes: Biochemical and Biophysical Evidence. International Journal of Molecular Sciences, 2019, 20, 2457.	4.2	27
10	A retinoic acid-dependent stroma-leukemia crosstalk promotes chronic lymphocytic leukemia progression. Nature Communications, 2018, 9, 1787.	13.0	24
11	Regulation of HIF-1 Î± in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role as a Therapeutic Target. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S214.	0.4	0
12	HIF-Î± factors as potential therapeutic targets in leukemia. Expert Opinion on Therapeutic Targets, 2018, 22, 917-928.	3.4	6
13	Lysine-Specific Demethylase 1A as a Promising Target in Acute Myeloid Leukemia. Frontiers in Oncology, 2018, 8, 255.	2.9	69
14	PML promotes metastasis of triple-negative breast cancer through transcriptional regulation of HIF1A target genes. Journal of Clinical Investigation, 2017, 2, e87380.	6.6	43
15	Reactivating nuclear PTEN to treat CLL. Oncotarget, 2017, 8, 35486-35487.	1.9	5
16	HIF-1Î± regulates the interaction of chronic lymphocytic leukemia cells with the tumor microenvironment. Blood, 2016, 127, 1987-1997.	1.4	52
17	24-Hydroxycholesterol participates in pancreatic neuroendocrine tumor development. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E6219-E6227.	7.5	40
18	Hypoxia inducible factor-1Î± regulates a pro-invasive phenotype in acute monocytic leukemia. Oncotarget, 2016, 7, 53540-53557.	1.9	24

#	Article	IF	Citations
19	A Genetic Platform to Model Sarcomagenesis from Primary Adult Mesenchymal Stem Cells. Cancer Discovery, 2015, 5, 396-409.	14.1	24
20	Synergistic Leukemia Eradication by Combined Treatment with Retinoic Acid and HIF Inhibition by EZN-2208 (PEG-SN38) in Preclinical Models of PML-RARÎ± and PLZF-RARÎ±â€"Driven Leukemia. Clinical Cancer Research, 2015, 21, 3685-3694.	7.2	41
21	Hallmarks of triple negative breast cancer emerging at last?. Cell Research, 2014, 24, 904-905.	12.1	46
22	A HIF-1 network reveals characteristics of epithelial-mesenchymal transition in acute promyelocytic leukemia. Genome Medicine, 2014, 6, 84.	8.5	20
23	<scp>HIF</scp> factors cooperate with <scp>PML</scp>â€<scp>RAR</scp>Î± to promote acute promyelocytic leukemia progression and relapse. EMBO Molecular Medicine, 2014, 6, 640-650.	6.8	37
24	A Dialog on the First 20 Years of PML Research and the Next 20 Ahead. Frontiers in Oncology, 2014, 4, 23.	2.9	11
25	Bone Marrow Endosteal Mesenchymal Progenitors Depend on HIF Factors for Maintenance and Regulation of Hematopoiesis. Stem Cell Reports, 2014, 2, 794-809.	4.7	25
26	Compound In Vivo Inactivation of Pml and p53 Uncovers a Functional Interaction in Angiosarcoma Suppression. Genes and Cancer, 2012, 3, 599-603.	1.8	4
27	Translationâ€dependent mechanisms lead to PML upregulation and mediate oncogenic Kâ€RASâ€induced cellular senescence. EMBO Molecular Medicine, 2012, 4, 594-602.	6.8	29
28	Myb-Binding Protein 1A (MYBBP1A) Is Essential for Early Embryonic Development, Controls Cell Cycle and Mitosis, and Acts as a Tumor Suppressor. PLoS ONE, 2012, 7, e39723.	2.5	43
29	Pml represses tumour progression through inhibition of mTOR. EMBO Molecular Medicine, 2011, 3, 249-257.	6.8	19
30	Absence of nucleolar disruption after impairment of 40S ribosome biogenesis reveals an rpL11-translation-dependent mechanism of p53 induction. Nature Cell Biology, 2009, 11, 501-508.	9.9	305
31	A novel signaling network as a critical rheostat for the biology and maintenance of the normal stem cell and the cancer-initiating cell. Current Opinion in Genetics and Development, 2009, 19, 51-59.	3.4	47
32	PML targeting eradicates quiescent leukaemia-initiating cells. Nature, 2008, 453, 1072-1078.	35.8	524
33	Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nature Reviews Molecular Cell Biology, 2007, 8, 1006-1016.	36.9	823
34	PML inhibits HIF-1Î± translation and neoangiogenesis through repression of mTOR. Nature, 2006, 442, 779-785.	35.8	360
35	The promyelocytic leukemia protein functions as a negative regulator of IFN-Â signaling. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 18715-18720.	7.5	37
36	The promyelocytic leukemia protein PML regulates c-Jun function in response to DNA damage. Blood, 2005, 105, 3686-3690.	1.4	48

#	Article	IF	Citations
37	Role of nucleophosmin in embryonic development and tumorigenesis. Nature, 2005, 437, 147-153.	35.8	517
38	Role of NPM in the Control of Genetic Stability and Tumorigenesis.. Blood, 2005, 106, 1595-1595.	1.4	0
39	Loss of the Tumor Suppressor PML in Human Cancers of Multiple Histologic Origins. Journal of the National Cancer Institute, 2004, 96, 269-279.	6.3	309
40	PML regulates p53 stability by sequestering Mdm2 to the nucleolus. Nature Cell Biology, 2004, 6, 665-672.	9.9	306
41	Mutations of the PML tumor suppressor gene in acute promyelocytic leukemia. Blood, 2004, 103, 2358-2362.	1.4	65
42	Role of PML and the PML-nuclear body in the control of programmed cell death. Oncogene, 2003, 22, 9048-9057.	5.9	176
43	The nucleolus: at the stem of immortality. Nature Medicine, 2003, 9, 24-25.	29.9	38
44	Effect of apoptogenic stimuli on colon carcinoma cell lines with a different c-myc expression level. International Journal of Molecular Medicine, 2003, 11, 737.	4.0	7
45	Modelling haematopoietic malignancies in the mouse and therapeutical implications. Oncogene, 2002, 21, 3445-3458.	5.9	45
46	Cdc25A stability is controlled by the ubiquitin-proteasome pathway during cell cycle progression and terminal differentiation. Oncogene, 2000, 19, 2447-2454.	5.9	70
47	Apoptosis-prone phenotype of human colon carcinoma cells with a high level amplification of the c-myc gene. Oncogene, 1999, 18, 439-448.	5.9	49
48	Multiparametric Staining to Identify Apoptotic Human Cells. Experimental Cell Research, 1997, 234, 174-177.	2.6	58
49	Analysis of poly(ADP-ribose) glycohydrolase activity in nuclear extracts from mammalian cells. BBA - Proteins and Proteomics, 1997, 1338, 60-68.	2.0	21
50	Poly(ADP-ribose) synthesis: a useful parameter for identifying apoptotic cells. The Histochemical Journal, 1997, 29, 831-837.	0.6	21